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Abstract
Helicobacter pylori (H. pylori) is well known as a group I human gastric cancer carcinogen
by the International Agency for Research on Cancer. Although an exact causal relation‐
ship is unclear, H. pylori is expected to have been associated with non-digestive abnormal
condition and/or diseases, such as metabolic syndrome, atherosclerosis and cardiovascu‐
lar diseases, which have substantially lots of prior studies; adaptive immune response –
related disorders, such as autoimmune thyroid diseases (ATDs), urticaria, atopy and
asthma; and the other extra-digestive diseases, such as chronic obstructive pulmonary
disease (COPD), migraine, anemia and hyperemesis gravidarum. This chapter overviews
several groups of extra-digestive diseases by H. pylori infection and discusses the role of
H. pylori in relation to the diseases in the viewpoint of causality.
Keywords: Helicobacter pylori, non- digestive diseases, overview, causality, relationship
1. Introduction
Helicobacter pylori (H. pylori), gram- negative spiral or curved bacillus, was discovered in 1982
by two pathologists, Barry Marshall and Robin Warren, the 1982 Nobel Prize awardees. Almost
all patients had active chronic gastritis or gastroduodenal ulcer and thus the bacteria got
attention as an important etiological factor of these diseases. Ironically, back to the past,
Freedburg and Barron had first found the spiral organisms among gastrectomy patients in
1940, but the bacteria were forgotten for a long time due to failure to replication in other studies.
H. pylori is an established cause of chronic active or superficial gastritis, gastroduodenal ulcer
disease, gastric adenocarcinoma and the mucosa-associated lymphoid tissue (MALT) lym‐
phoma. The International Agency for Research on Cancer (IARC), a suborganization of the
World Health Organization (WHO), classified the H. pylori as a group I human gastric cancer
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carcinogen (the meaning of definite carcinogen) in 1994. H. pylori chronic infection to gastric
tissue results in carcinogenic environment or causes chronic inflammation, which leads to
gastric carcinogenesis. Chronic H. pylori infection also induces gastric lymphoid follicles and
trigger MALT lymphomagenesis of lymphoid expansion, which leads to MALT lymphoma.
Although only a few people (1–3%) with H. pylori chronic infection develop gastric cancer, H.
pylori explains a 60–90% of gastric cancer in studies of population attributable fraction (PAF)
estimation.
Prior studies showed that H. pylori is also expected to be associated with extra-digestive
diseases. The first group of diseases is abnormal metabolic profiles such as insulin resistance,
diabetes, hypertension, obesity and dyslipidemia, which are the components of metabolic
syndrome. Consequently, the abnormal profiles are complexly influenced to increase the risk
for cardiovascular diseases by atherosclerosis and vascular dysfunction. The second group of
diseases is adaptive immune response–related disorders, such as autoimmune diseases
including autoimmune thyroid diseases (ATDs), atopic disease, urticaria and asthma. The
other group is on elusive knowledge, such as COPD, glaucoma, migraine, anemia and
hyperemesis gravidarum.
The suggested mechanism, despite of inconclusive causal relationship, is as follows: Chronic
H. pylori infection induces chronic inflammation, a complex biological response of the tissues
to H. pylori. Inflammatory factors including cytokines interleukin (IL) and tumor necrosis
factor (TNF), especially induced from chronic, low-grade inflammation, on the infection-
inflammation pathway are common in pathogenesis of gastritis, atherosclerosis, metabolic
syndrome, obesity and diabetes. These inflammatory factors produced in the inflamed gastric
mucosa are continually secreted into the circulation, and they can affect metabolic profiles.[1]
Therefore, chronic, low-grade inflammation by chronic H. pylori infection may induce extra‐
gastric diseases due to the effect of H. pylori–induced cytokines.
H. pylori infection and its transmission were related to low socioeconomic status (SES) such as
poor hygiene, water contamination, and non-healthy lifestyles such as poor diet, smoking and
physical inactivity. Usually people who were tested with H. pylori infection are those in middle
SES class and over, and therefore, non-gastric diseases are also diagnosed in this class. Poor
hygiene hypothesis seems to be no more proper for these populations in the association of H.
pylori infection with non-gastric diseases.
Therefore, this chapter introduces extradigestive diseases by H. pylori infection and discusses
critical issues in the H. pylori role in extradigestive diseases in the viewpoint of causality of H.
pylori infection for these diseases.
2. Dyslipidemia
Dyslipidemia, such as high total cholesterol and/or triglyceride concentration or low high-
density lipoprotein (HDL) level, is a component for metabolic syndrome (MetS). Abnormal
lipid profile in H. pylori–infected subjects has been reported in several studies. A review paper
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for dyslipidemia using 8 related articles[1] showed that H. pylori infection patients had higher
levels of plasma total cholesterol, low-density lipoprotein (LDL)-cholesterol and/or triglycer‐
ide, but lower levels of high-density lipoprotein (HDL)-cholesterol relative to non-infected
patients. These conditions were significantly replicated in 5,077 Japanese men only in a large
population study for H. pylori eradication therapy, but failed to replicate it in women due to
small number of woman patients.[1, 2] However, Satoh et al. showed significant associations
between H. pylori infection and LDL or HDL levels only in male subjects and there was no
significant association between H. pylori seropositivity and triglyceride concentration in the
same study.[2] It is postulated that overexpression of various cytokines, such as IL-6 and TNF-
α by H. pylori infection, may stimulate production of fatty acids by activating lipoprotein lipase
in adipose tissue. Successful eradication treatment of H. pylori may induce an increase of HDL
and decrease of LDL and triglycerides, but the alteration of blood lipid profiles before and
after eradication therapy is not consistent in the total five observational studies and clinical
trials.[1]
3. Hypertension
Hypertension is a component of MetS. Various cytokines induced by H. pylori infection in
gastric mucosa may stimulate the hypothalamus and brain stem, which leads to sympathetic
activation by secretion of cortisol and adrenaline. The subsequent pathway may induce the
high blood pressure.[3] Although Harvey et al. reported the significantly positive association
of H. pylori infection with hypertension in the community-based Bristol helicobacter project
with the 10,537 subjects, the relationship is likely to be the result by residual confounding
factors. Although a paper for African people showed decreased levels of blood pressure levels
after three weeks of H. pylori eradication treatment,[4] it is likely to be not causally related
because the study is not placebo controlled and remains misclassification bias because H.
pylori test is not performed after treatment.
4. Insulin resistance and diabetes
Insulin resistance (IR) is one of important componnents on type 2 diabetes mellitus (DM)
pathogenesis. In a systematic review published in 2011, a significantly high homeostatic model
assessment-insulin resistance (HOMA-IR) score in H. pylori–infected population than non-
infected population was reported in seven cross-sectional analyses.[5] In two non-randomized
trials for H. pylori eradication therapy, a study showed a beneficial effect of H. pylori eradication
therapy with decreased IR score in successfully eradicated patient group, but the other study
failed to prove it. The potential mechanisms are suggested as follows: Lipopolysaccharides
from H. pylori link to the activation of Toll-like receptors (TLRs), expressed mainly in macro‐
phages and dendritic cells, which results in energy harvesting, fat accumulation and conse‐
quently IR.[6] And higher inflammatory cytokines can inhibit insulin action on its receptor
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through phosphorylation of serine residues on the insulin receptor and consequently induce
insulin insensitivity and resistance.[5]
However, despite of statistical association between H. pylori infection and IR, there is contin‐
ually arguing among investigators. The reasons are due to inconsistent result in comparison
of IR status in pre– and post–H. pylori eradication therapy in a systematic review.[5] There
were three non-randomized trials: two reported beneficial effects of H. pylori eradication
therapy in decreasing IR score,[7] but the others [8] reported non-association and non-changes
in the levels of IR in pre- and post-therapy regardless of eradication treatment.[5-7]
Three meta-analysis papers were reported up to date. In a meta-analysis using 41 diabetes and
non-diabetes comparison studies in 2013, H. pylori infection was reported to be higher in
patients with diabetes compared with non-diabetic patients,[9] and in the other meta-analysis
using 13 case-control studies published in the same year, H. pylori infection was also associated
with a 2-fold higher risk for diabetes among 13 case-control studies and at 1.6-fold higher risk
for diabetic nephropathy among 6 case-control studies.[10] Both meta-analyses showed the
action of H. pylori infection was stronger in type 2 diabetes than in type 1 diabetes.[9, 10]
The first prospective cohort study, published in 2012, of 782 diabetes-free subjects with 5-year
follow-up presented that H. pylori–infected subjects had 2.7-fold higher risk for type 2 diabetes
relative to non-infected people.[10, 11] However the other prospective cohort study, published
in 2012, with 10-year follow-up did not show significant association between H. pylori infection
and DM.[10–12] Moreover, meta-analysis of two cohort studies did not show any relationship.
The inconsistency across the studies is due to non-overcoming reverse causation and recall
bias. The positive result in the first cohort study may be due to the finding secondary to the
higher proportion of other risk factors of diabetes in H. pylori–infected group relative to non-
infected group. Considering the results of the two cohort studies, it can be inferred that the
significant effect of H. pylori infection on the development of diabetes may exist in only earlier
life within 5-year follow-up and disappear or weaken due to risk factors of diabetes for long-
term follow-up. Thus, the debate in causality for the association between H. pylori infection
and diabetes has been still around.
5. Obesity
Although changes in ghrelin, a peptide hormone produced in the gastrointestinal tract, in
relation to appetite or weight gain and in leptin, a hormone secreted from adipose tissue, in
relation to inhibition of hunger and storage of triglycerides in adipocytes are suggested to be
associated between obesity and H. pylori infection, there was inconsistent association across
prior observational studies. Although the data regarding association between obesity and H.
pylori infection are uncommon, most of the studies are cross-sectional design, non-overcoming
reverse causation. The prior results are controversial across studies such as positive relation‐
ship (more obese in H. pylori infected people relative to non-infected people) and non-
relationship.[1] Body mass index (BMI) after successful H. pylori eradication is expected to be
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decreased. However two non-randomized[13, 14] and a randomized placebo-controlled trial
studies showed that BMI after successful H. pylori eradication was rather increased.[12]
6. Metabolic syndrome
The metabolic syndrome (MetS) is a group of five components: central obesity (waist circum‐
ference ≥102cm or 40 inches in male and ≥ 35 inches in female); high blood pressure (≥130/85
mmHg, and fasting plasma glucose ≥6.1 mmol/L); triglyceride dyslipidemia (triglyceride levels
≥1.7mmol/L); HDL-cholesterol dyslipidemia (high density lipoprotein-C (HDL-C) <40mg/dl
in male and <50mg/dL in female); and hyperglycemia (fasting plasma glucose ≥6.1 mmol/L).
By the standard of the US National Cholesterol Education Program Adult Treatment Panel III
(NCEP III), MetS requires at least three of the five components. Many studies concerned the
association between H. pylori infection and extradigestive manifestation. Relation of H. pylori
infection with the MetS was evaluated in several studies.
Nabiour et al. first evaluated the association between H. pylori infection and MetS in 2006.[13]
Compared with the group not infected by H. pylori, the group with H. pylori infection showed
1.5-fold significantly elevated risk for the MetS in both men and women. Association between
H. pylori eradication treatment and remission of the MetS was evaluated to investigate the
effect of H. pylori infection on the pathogenesis of the MetS. According to the study among
Black people by Longo-Mbenza et al.,[4] three components such as plasma glucose, systolic
and diastolic blood pressure and HDL-cholesterol levels were significantly improved com‐
pared with baseline values after three weeks of H. pylori eradication treatment. However, the
two studies are cross-sectional small-numbered design; it is not obvious whether the observed
difference is due to the anti-inflammatory or confounded effects by other risk factors than H.
pylori eradication effects.[4] Also prior studies for the association of H. pylori infection for each
MetS component failed to show its clear relationship. Therefore, further cohort studies with
larger sample size need to be performed to confirm the relationship between MetS and its
components and H. pylori infection, especially infection to highly virulent H. pylori such as
CagA-strain.
7. Atherosclerosis and related diseases
Recent data have implicated H. pylori in atherosclerosis. Atherosclerosis, arteriosclerotic
vascular disease, is a condition of artery wall thickness by complex pathogenesis of invasion
and accumulation of white blood cells (WBCs) and proliferation of intimal smooth muscle cells
by fatty fibrinogen plaque. It occurres due to chronic inflammation of WBCs and is promoted
by residues of dead cells, including cholesterol and triglycerides. It can increase cardiovascular
and cerebrovascular morbidity and mortality.
Biologically, H. pylori infection to gastric tissue can induce inflammatory cytokines, such as c-
reactive protein (CRP), IL-series including 1, 6, 18, etc, and TNF-α, which leads to systemic
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inflammation. H. pylori infection can modify asymmetric dimethylarginine (ADMA) and
inhibit absorption of vitamin B12 and folic acid in stomach, which also causes hyperhomocys‐
teinemia.
Moreover, a virulent H. pylori strain, vacuolating cytotoxin A (VacA)-secreting H. pylori,
infection can directly stimulate hyperhomocysteinemia. Cross-reaction between H. pylori
antigens such as cytotoxin-associated gene A (CagA) and heat shock proteins (HSPs) produces
autoimmune response by realizing it as a molecular mimicry of autoimmune antigen. Systemic
inflammation by cytokine reaction, cytokines themselves as pro-atherogenic mediators,
prohyperhomocysteinemia and autoimmune response complexly affect, thereby causing
dysfunctional microvessels and inducing growth of vascular epithelial cells. H. pylori infection
can also increase dyslipidemia, oxidative stress, and platelet aggregation. Subsequently these
processes complexly induce and aggravate atherosclerosis.[14, 15] Additionally, pro-athero‐
genic cytokines activate hypothalamus and brain stem, which subsequently increase sympa‐
thetic hormones such as cortisol and adrenalin and result in hypertension, insulin resistance
and dyslipidemia. These sequential pathological conditions finally lead to the cardiovascular
diseases such as ischemic heart disease and ischemic stroke.[17, 18]
A prior case-control study of atherosclerosis measured by carotid intima-media thickness
showed that H. pylori–infected people had higher carotid intima-media thickness than non-
infected people and H. pylori infection increased the risk for atherosclerosis.[14] A prospective
cohort study for 5-year follow-up showed the CagA-strain–infected group had much higher
changes in intima-media thickness of common carotid arteries (IMT-CCA) and even developed
new atherosclerotic lesions.[16] This study suggests that H pylori infection, in particular the
more virulent H. pylori infection of CagA-strain, can be associated with atherosclerosis risk,
perhaps due to an enhanced immune inflammatory response.
In contrast, the link between H. pylori infection and ischemic heart disease and stroke seems to
be still left as unresolved issue due to divergent results. There are two meta-analyses for ischemic
heart disease and two meta-analyses for coronary heart disease (CHD) events or death up to
date. For ischemic heart disease, the meta-analyses of 10 case-control studies published in 2006
and of 26 case-control studies published in 2015 presented that H. pylori infection was associat‐
ed with 1.87-fold and 2.1-fold higher risk for ischemic heart disease, respectively.[17, 18] Liu et
al.’s summary risk was consistent, regardless of ethnicity and age (range 1.75–2.29).[18] For
CHD, a meta-analysis of 15 case-control studies, published in 2008, presented that CagA had a
2.1-fold higher risk for CHD (Zhang et al.), and the other meta-analysis of 3 cohort studies,
published in 2008, also presented a 1.26-fold higher risk for CHD (Pasceri et al., 2006). Howev‐
er, most recent meta-analysis, published in 2015, of 19 prospective cohort studies reported a
debatable result: the significant effect was weaker (only 11% increase in the risk of CHD) and
existed in only patients’ early lives within follow-up of 5 years and the association was not seen
at 10-year follow-up due to masking effect by CHD risk factors (Sun).
Meta-analyses for ischemic stroke, two published in 2008 and one in 2006, respectively,
summarized results from case-control and cross-sectional studies and reported an increasing
risk for ischemic stroke by H. pylori infection (Wang et al., 2008, a 1.6-fold higher risk by H.
pylori infection including CagA; Pasceri et al., 2006, a 2.4-fold higher risk by CagA strain
infection; Zhang et al., 2008, a 2.7-fold higher risk by CagA strain infection). However, a recent
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meta-analysis of six cohort studies and four nested case-control/case-cohort studies failed to
prove the association (Yu), regardless of CagA virulence, study design, number of pathogens,
and study quality (Yu). Case-control or cross-sectional designs have a higher possibility in
overwhelming risk by their small size and consequently selection bias and insufficient
adjustment for confounders. Therefore, the summary risk in meta-analysis of prior case-control
and cross-sectional studies may be augmented relative to real risk value. Association between
H. pylori infection and the risk of ischemic stroke up to date seems to be inconclusive.
8. Adaptive immune response relating disorders
Autoimmune disease develops when adaptive immune response induced by H. pylori–infected
cells develops and autoantibodies are pronouncing against self-antigens, such as thyroid
antigens,[19] circulating IgE or alpha-chain of the high-affinity IgE receptor.[20] Autoimmune
diseases by H. pylori infection, autoimmune thyroid diseases (ATDs) and chronic urticaria (CU)
have been reported. For ATDs, a meta-analysis of seven observational studies involving a total
of 862 patients, published in 2013, indicated that H. pylori infection, especially CagA, was
associated with 1.92-fold higher risk for total ATDs, and there is no heterogeneity and
publication bias. In subgroup analysis, H. pylori infection was at 4.35-fold higher risk for
Graves’ disease, while Hashimoto’s thyroiditis was not associated with H. pylori infection.[19]
For urticaria, a meta-analysis of nine case-control studies with high quality indicated that H.
pylori infection was at 1.36-fold higher risk for CU (no heterogeneity and publication bias).[20]
However, both meta-analyses fundamentally did not overcome the possibility of confounders
and the problem of reverse causation and bias in meta-analysis using case-control studies,
although the findings suggest H. pylori potentially plays a part in the development of ATDs
and CU.[22, 23]
For atopy/allergic disease, a meta-analysis of 17 case-control studies performed in Western
countries, published in 2014, showed a significant inverse association of H. pylori infection,
perhaps by link of a better hygiene related to decrease of H. pylori infection and the large
spreading of atopic diseases.[21] The mechanism of allergy is different from ATD. H. pylori
infection may evoke immune tolerance, which is an overactive Th2 response by lack of the Th1
response, which facilitates persistent infection and inhibits allergic T-cell responses.[21] This
mechanism is applied to asthma. A meta-analysis, published in 2012, of five case-control
studies failed to show an association between H. pylori infection and asthma,[22] while the
other meta-analysis, published in 2013, of 14 case-control and cross-sectional studies showed
the opposite result, which is a significant reduced risk for asthma by H. pylori infection
(OR=0.84), but had significant heterogeneity across studies.[23]
9. Other extra-digestive diseases
For COPD and CB, a meta-analysis, published in 2015, of 16 studies demonstrated that H.
pylori infection had a 2.07-fold and 1.57-fold increased risk for Chronic obstructive pulmonary
Extra-digestive Manifestations of Helicobacter pylori Infection – An Overview
http://dx.doi.org/10.5772/63226
9
disease (COPD) and chronic bronchitis (CB) risk, respectively. CagA-strain H. pylori infection
had much higher risk for COPD up to 3.46-fold. There are no heterogeneity and publication
bias.[24] Although H. pylori infection on the etiology of CB and COPD remains controversial,
two hypothetical mechanisms are suggested: 1) H. pylori infection may cause direct lung tissue
damage, which leads to COPD and chronic bronchitis; 2) H. pylori infection triggers both
diseases through sequential reaction of inflammatory cytokines.[24]
For migraine, a meta-analysis[25], published in 2014, of five cross-sectional studies showed
that H. pylori infection had significantly 1.92-fold higher risk. However there are heterogene‐
ity  and publication bias  across  studies.  Despite  of  its  inconclusive  result,  the  suggested
mechanism is that H. pylori infection in stomach triggers inflammation, which stimulates the
gastrointestinal neuroendocrine cells to secrete neuroendocrine peptides because migraine
originates from the gastrointestinal organ. This sequential process may result in migraine by
the brain-gut axis.[25]
For iron deficiency anemia (IDA), a meta-analysis,[26] published in 2010, of 15 case-control
studies showed that H. pylori infection had significantly 2.22-fold higher risk. However, H.
pylori eradication therapy in five RCTs was not efficient in improving hemoglobin and ferritin
levels.[26] Both meta-analysis results had a publication bias and heterogeneity across the
studies. The association is not causally related because IDA is specifically related to H. pylori
infection and confounded by other risk factors.
For hyperemesis gravidarum (HG), a meta-analysis,[27] published in 2015, of 32 cross-sectional
and case-control studies demonstrated a significantly 3.34-fold higher risk by H. pylori
infection; however, there is heterogeneity across the studies. Hypothetical pathogenic mech‐
anism is that H. pylori infection induces oxidative stress status by increasing reactive oxygen
species (ROS) and decreasing plasma antioxidants, such as vitamin C and antioxidant
enzymes, such as superoxide dismutase (SOD), catalase (CT) and glutathione peroxidase
(GSH-Px).[27]
10. Summary and Conclusion
Most studies for extra-digestive diseases up to date are cross-sectional or case-control studies,
with small sample size. There are several cohort studies, but the results are diverse. Cross-
sectional or case-control designs are more susceptible to bias than cohort or clinical trial design.
H. pylori infection was diagnosed by different methods up to date, which cause different H.
pylori infection prevalence according to each assay method and affect heterogenous meta-
analysis result across studies. Therefore, evidence as to what impact the H. pylori infection,
especially highly virulent H. pylori infection such as CagA-strain infection, would have on the
development of extra-digestive diseases concerned in lots of prior studies seems to be
inconclusive. Large-scale, multicenter-based prospective cohort or clinical trial studies are still
required to clarify the etiology between H. pylori and extra-digestive diseases because of the
limited number of studies included in meta-analysis, their small sample sizes and inclusion of
study design with low quality on causality reasoning evidence.
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